FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

Investigation raises serious questions about the harm-benefit balance of Rexulti; the Decision may reverse efforts to reduce the use of antipsychotics in US care homes. During testing, the antipsychotic medication brexpiprazole (Rexulti) did not demonstrate a significant therapeutic effect and was

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug

FDA rushes approval of dementia drug that quadruples risk of death

FDA rules Otsuka marketing claim overstates Rexulti efficacy

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

FDA's Fast-Track for Rexulti Raises Concerns

Low-Dose Tramadol as an Off-Label Antidepressant: A Data Mining

Fast-Track Drug Approval, Designed for Emergencies, Is Now Routine

Norman DeLisle on LinkedIn: Michigan's seven-day average highest

FDA Takes Tougher Line on Fast-Tracked Drugs - WSJ

Pharmaceutical payments to psychiatrists and betrayal of the